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Background: Treatment of patients with multimorbidity is challenging. A rational reduction of long-term drugs can
lead to decreased mortality, less acute hospital treatment, and a reduction of costs. Simplification of drug treatment
schemes is also related to higher levels of patient satisfaction and adherence. The POLITE-RCT trial will test the
effectiveness of an intervention aiming at reducing the number of prescribed long-term drugs among multimorbid
and chronically ill patients. The intervention focuses on the interface between primary and secondary health care
and includes a pharmacist-based, patient-centered medication review prior to the patient’s discharge from hospital.
Methods: The POLITE-RCT trial is a cluster randomized controlled trial. Two major secondary health care providers
of Mecklenburg-Western Pomerania, Germany, take part in the study. Clusters are wards of both medical centers.
All wards where patients with chronic diseases and multimorbidity are regularly treated will be included. Patients
aged 65+ years who take five or more prescribed long-term drugs and who are likely to spend at least 5 days in
the participating hospitals will be recruited and included consecutively. Cluster-randomization takes place after a
six-month baseline data collection period. Patients of the control group receive care as usual. The independent
two main primary outcomes are (1) health-related quality of life (EQ-5D) and (2) the difference in the number of
prescribed long-term pharmaceutical agents between intervention and control group. The secondary outcomes
are appropriateness of prescribed medication (PRISCUS list, Beers Criteria, MAI), patient satisfaction (TSQM), patient
empowerment (PEF-FB-9), patient autonomy (IADL), falls, re-hospitalization, and death. The points of measurement
are at admission to (T0) and discharge from hospital (T1) as well as 6 and 12 months after discharge from the
hospital (T2 and T3). In 42 wards, 1,626 patients will be recruited.
Discussion: In case of positive evaluation, the proposed study will provide evidence for a sustainable reduction of
polypharmacy by enhancing patient-centeredness and patient autonomy.
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Along with demographic and epidemiologic changes,
polypharmacy becomes a pressing challenge. More and
more people suffer from chronic diseases and multi-
morbidity [1-3] and are treated with an increasing
number of drugs. Whereas polypharmacy usually refers
to the intake of five or more long-term drugs at the same
time [4,5], patients with multiple chronic diseases are
often treated with ten or more drugs [6-8]. In Germany,
the prevalence of polypharmacy among elderly patients is
about 27% and doubles to 54% when including over-the-
counter medications (OTC) [9].
Treatment of patients with multimorbidity is challenging;
medical guidelines tend to focus on a solitary chronic dis-
ease. In patients with several chronic diseases conflicting
recommendations are likely to occur. Polypharmacy, thus,
involves severe risks for patient safety; it is associated with
a reduced ability to perform tasks of daily living, with
an increased risk for impaired cognitive capacity, and
with rising incidence of geriatric syndromes, such as
delirium, falls, and urinary incontinence. In addition,
patients with polypharmacy witness an increased rate of
adverse drug events and drug interactions [10-12]. Among
geriatric patients, 10%–15% of all hospital admissions are
related to adverse drug events [13]. Adverse drug events
increase both morbidity and mortality [12-15]. Previous
research shows that a reasonable reduction of long-term
drugs can lead to decreased mortality, less acute hospital
treatment, and a reduction of costs. Simplification of drug
treatment schemes is also related to higher levels of
patient satisfaction and adherence [5,14,16-20].
In the past, different tools have been developed to assess
and optimize medication in chronically ill patients. In
1991, Beers et al. presented a first catalogue of criteria to
detect inappropriate substances among older people—the
Beers Criteria for Potentially Inappropriate Medication
Use in Older Adults [20,21]. Due to different “markets”
and prescribing behavior, countries such as Canada,
France, and Germany created their own lists of potentially
inappropriate medication (PIM). In 2010, the first German
PIM list was published; the PRISCUS list is based on
international literature and specific characteristics of
Germany. It is systematically consented by experts in the
field [22,23].
Furthermore, the usage of OTCs is rising steadily.
Very often, though, patients do not perceive OTCs as
medication. Although nearly 30% of German adults
periodically make use of herbal preparations—primarily
as dietary supplements—they rarely report the usage
to their doctors [24,25]. Among patients with multi-
morbidity, who are using a high number of drugs,
these dietary supplements can cause severe drug inter-
actions such as bleeding [26] or reduced plasma drug
levels [27].Interventions relying on a concept where pharmacists
provide information to clinicians have shown effects on
reducing inappropriate prescriptions [12]. Standardized
prescription-feedback [28] and educational outreach visits
also showed to have some effect towards the reduction of
inappropriate multiple medication [12,16,17]. Studies have
been conducted in different settings, however, focusing
mainly on nursing homes or secondary care. Despite
promising results [11,14,29,30], there is still a lack of
robust evidence on the sustainability of the effects of
medication reviews [31]. Whereas some trials lacked a
control group [9,12], others failed to reduce polypharmacy
in the long run [5,32,33]. As far as the latter are con-
cerned, patients’ and primary care physicians’ preferences
to switch back to the previous medication scheme have
been identified as a major problem [34-37]. In sum,
there is evidence for the efficacy of well-planned and
performed interventions to reduce polypharmacy.
However, evidence for effectiveness and efficiency is
still lacking, especially as far as effects on patients’
quality of life are concerned [38].Objectives
The POLITE-RCT trial will test the effectiveness of an
intervention aiming at reducing the number of prescribed
long-term drugs among multimorbid and chronically ill
patients aged 65+ years. The intervention focuses on the
interface between primary and secondary health care and
includes a pharmacist-based, patient-centered medication
review prior to the patient’s discharge from hospital. This
approach is innovative and particularly promising, as
hospitalization of older, multimorbid and chronically ill
patients is often related to an increase in the number of
prescribed long-term drugs [39,40]. It will be the first trial
to systematically assess the effectiveness of the des-
cribed intervention which is based on both evidence
and patient preferences. The POLITE-RCT trial is built
on previous research; the POLITE pilot study proved
that the intervention is feasible. Reactions of patients,
pharmacists, ward physicians, and general practitioners
(GPs) were positive. On average, the number of prescribed
long-term pharmaceutical agents was reduced by one per
patient [8,41].Methods
Trial design
The POLITE-RCT trial is a cluster randomized con-
trolled trial. Two major secondary health care providers
of Mecklenburg-Western Pomerania, Germany, will take
part in the study. Together, both centers with a total of
four hospitals treat about 80,000 patients a year in urban
and rural settings. The study will, thus, be conducted in
a setting that represents the real health service situation.
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Clusters are wards of both medical centers including
medical personnel and patients cared for during the
observational periods. A ward is defined as an entity
with stable medical personnel. In case of responsibility
of senior physicians for two or more wards, these wards
will be randomized together.
Inclusion criteria
All wards of the participating centers where elderly
patients with chronic diseases and multimorbidity are
regularly treated will be included. These are, e.g., units
of internal medicine, geriatrics, abdominal and vascular
surgery, orthopedic surgery, and neurology.
Exclusion criteria
Wards currently participating in other trials or projects
aiming at optimizing drug therapy will be excluded.
Participants
Inclusion criteria
Patients aged 65+ years who take five or more prescribed
long-term drugs that are systemically acting (topic admin-
istration excluded) and who are likely to spend at least
5 days in the participating hospitals will be recruited and
included consecutively.
Exclusion criteria
Patients who are not able to take their medication by
themselves, who are not able to give legal informed
consent (e.g., due to dementia), patients with severe
language difficulties, and those who suffer from deafness
as well as patients taking part in another clinical trial will
be excluded. Further, patients with the following diseases
that usually make polypharmacotherapy unavoidable are
excluded: active malignoma, acquired immunodeficiencies
(HIV), and hemodialysis. Also, post-transplant patients as
well as patients having a remaining life expectancy of less
than 12 months will be excluded.
Recruitment
Each week, up to 30 eligible patients will be recruited
per hospital consecutively at admission. Pharmacists will
inform about the study and will seek written informed
consent. Recruitment will be stopped as soon as the
necessary number of patients per week is reached.
Randomization
Cluster randomization takes place after a 6-month baseline
data collection period. During this period, no intervention
will be performed. This allows collecting information about
potential confounders and cluster imbalances. Based on
that, the decision for or against stratified randomization
will be made. Computer-assisted randomization will beperformed by a statistician not involved in patient recruit-
ment, data collection, and data management.
Intervention
During in-patient treatment of patients affected by poly-
pharmacy, a pharmacist specially trained in communication
skills performs a narrative-based medication review. Thus,
two approaches are combined here: the face-to-face clinical
“brown bag” medication review [42] and the patient-
centered approach of narrative medicine [43,44]. Apart
from detecting potentially inadequate medication, a major
aim is to identify patient preferences and to include
them—whenever possible—into a hierarchically structured
list of evidence-based medication recommendations.
Thus, priorities for medication modification can be based
on both “objective” pharmaceutical considerations as well
as on “subjective” patient preferences. The pilot study
showed that this approach motivated patients to ac-
tively contribute to the reduction of medication. The
narrative-based medication review itself takes approxi-
mately 30–45 min. The pharmacist then prepares a list of
possible drugs to be stopped. Pharmacists have access
to a clinical decision support system [45]. The list will
be discussed with the hospital physician in charge and will
be submitted for adjustment with the patient’s individual
GP. The active involvement of the patient’s GP aims at
bringing transparency into the decision-making and might
increase chances for a sustainable optimization of medica-
tion by preventing relapse to old medication patterns (as
frequently observed in other studies). See Figure 1.
Control group
Patients attending wards randomized into the control
group will not receive a medication review but receive
care as usual. Medication data will be obtained from
patient records. Contamination between control and
intervention group will be minimized by careful and
strict separation of functional units.
Outcomes
Primary outcomes
The independent two main outcomes are (1) health-related
quality of life (EQ-5D) [46-48] and (2) the difference in the
number of prescribed long-term pharmaceutical agents
between intervention and control group at T3. Since in
Germany, combination drugs are frequently used, the
primary outcome focuses on pharmaceutical agents rather
than on number of drugs.
Secondary outcomes
The secondary outcomes are appropriateness of prescribed
medication (PRISCUS list [22], Beers Criteria [49,50], MAI
[51,52]), patient satisfaction (TSQM) [53,54], patient




















Figure 1 The intervention cascade.
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and death. For all patients ensured with the largest
public German health insurance provider AOK, cost-
effectiveness will be analyzed by the Scientific Institute of
the AOK (WIdO). In addition, data on socio-demographic
characteristics [58] will be collected. See Table 1.
Points of measurement
Prior to the intervention, baseline data will be collected.
During the following intervention period, for each patient
of the intervention and control group, primary outcomes
will be measured at four points in time: at admission to
(T0) and discharge from hospital (T1) as well as 6 and
12 months after discharge from the hospital (T2 and T3).
Blinding
Patients, pharmacists, physicians, study assistants, and
statisticians will not be blinded. Only at T2 and T3,
pharmacists will be blinded for data collection.Table 1 Overview of instruments and time of measurements
Outcome Instrument
Primary outcomes
Health-related quality of life EQ-5D
Difference in the number of prescribed
long-term pharmaceutical agents
Number of prescribed long-term
Secondary outcomes
Appropriateness of prescribed medication PRISCUS list, Beers Criteria
Medication appropriateness inde
Patient satisfaction TSQM
Patient empowerment 9-item shared decision-making q
Patient autonomy Instrumental activities of daily livi
Falls Frequency: number of falls in the
For each fall, severity will be asses
Moderate: bruising, sprains, cuts, a
for at least three days or if partic
Severe: fractures, admission to ho
Re-hospitalization
Death
Cost-effectiveness Difference in health care costs be
Additional data
Demographic data Socio-demographic characteristicSample size
For the two independent primary outcomes of (1) health-
related quality of life (EQ-5D) and (2) the difference in
prescribed long-term pharmaceutical agents between
intervention and control group at 12 months after
discharge (T3), the following assumptions are made: for
the single summary index of the five dimensions of the
EQ-5D descriptive part (using reference value sets for
Germany) for the changes from T0 to T3, a mean clinical
relevant difference of 0.1 with standard deviation of 0.3
shall be demonstrated between intervention and control.
For the difference in prescribed long-term pharmaceutical
agents between both groups at 12 months after discharge
(T3), a mean difference of 0.5 (number of agents) in
reduction of agents with an expected standard deviation
of about 1.5 has to be proven. If an EQ-5D difference of
0.1 with standard deviation of 0.3 (or a mean difference of
0.5 in reductions of agents with an expected threefold
standard deviation) is to be demonstrated with a power ofTime of measurement
T0 T1 T2 T3
X X X
pharmaceutical agents X X X X
X X X X
x (MAI) X X X X
X X X
uestionnaire (PEF-FB-9) X X X
ng scale (IADL) X X X
previous 6 months X X X X
sed:
brasions, or reduction in physical function
ipant sought medical help
spital with an injury, or if stitches were required
X X
X X X
tween both groups X
s in epidemiological studies (SDD) X X X
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of 143 per group will be required in a randomized trial.
For the cluster randomized trial, this sample size has to be
multiplied by a design factor of 5.4 [59] if an intra-class
correlation coefficient (ICC) of 0.1 and a cluster size of 40
patients is assumed, resulting in a sample size of 1,545
evaluable patients in 38 clusters. Assuming a dropout rate
of 5%, a total sample size of 1,626 patients in 42 wards
has to be recruited initially. The number of patients per
cluster was conservatively defined in order to cope with
possible variations that could not be taken into account
at the start of the trial. Therefore, sample size estimations
will be verified by results of the baseline data analysis. If
necessary, adjustments of sample size estimations will be
realized. See Figure 2.Data collection, quality, and monitoring
The personnel of the participating wards will not be
involved in data collection. Instead, data collection will be
performed by trained pharmacists and study assistants.
Pharmacists will also perform telephone data collection
at T2 and T3 and will not receive information about
group affiliation of patients. To reduce selection bias,
a standardized and scrupulously followed recruitment
procedure will be employed, supervised by research
assistants and monitored by the Clinical Trial Center
North at the University Hospital Hamburg-Eppendorf
(CTCN). Monitoring will be conducted according to
the standard operation procedures of the Clinical Trial
Center North and in compliance with the E6 ICH GCP
guideline for good clinical practice. Clinical monitoring
will also include review and resolution of missing or
inconsistent results and source document checks (i.e.,
comparison of submitted study results to original reports)
to assure the accuracy of the reported data.Statistical methods
The unit of inference will be the individual. Then, ana-
lyses will be carried out at cluster and at individual level.
In a first simple approach, data in each cluster will be
collapsed to construct a relevant summary measure
(mean with standard deviation). This essentially removes
the need to adjust for clustering effects. Of course, for
variable-sized clusters, this analysis does neither take
into account the intra-cluster correlation nor the cluster
sizes and is less efficient than an individual-level analysis.
But nevertheless, the relative simplicity of a cluster-level
analysis still remains an advantage, albeit with some loss
of efficiency and an inability to adjust for individual-level
risk factors. In a second step, generalized estimating equa-
tions (GEE) models will be applied [60,61]. A generalized
linear model takes into account within-group correlation
and allows adjustment for the joint effects of cluster-levelas well as individual-level factors without the requirement
of parametric assumptions.
A model that takes into account the randomized clusters
(wards) as random effect, with EQ-5D change or difference
in prescribed long-term pharmaceutical agents between
intervention and control at T3 as dependent and random
group as independent variables, will be fitted to the data.
In this model, baseline (T0) values of primary variables
and a selection of further baseline characteristics of ward
or patient will function as covariates. The intervention
effects are quantified by the between-group differences of
the corresponding estimates of changes from baseline
from the fully adjusted model, which we assume to give
the best account of the study results. In the statistical
analyses, missing values will not be replaced. Methods
for dealing with outliers will be defined in the statistical
analysis plan (SAP) or in an addendum to the SAP.
Secondary efficacy variables will be analyzed in an explora-
tive way. Similarly, confidence intervals computed will be
interpreted as interval estimates for presence or absence
of effects in the study data. Intention-to-treat analyses will
be performed.
Stopping rules
Data on death (T1, T2, T3) and hospital re-admissions
(T2, T3) of the included patients will be collected. If signifi-
cant differences in the re-admission rate or number of
deaths will be discovered, the safety board will be informed
to decide whether to stop or continue the trial.
Ethical approval
The study was approved by the Ethics Committee at the
Rostock University Medical Center in June 2014 with
the reference A 2014–0101.
Study registration
The study has been registered with Current Controlled
Trials Ltd. with the reference ISRCTN42003273.
Trial status
Patient recruitment and baseline data collection started
in August 2014.
Discussion
The POLITE-RCT trial focuses on the pressing challenge
of reducing inappropriate medication among elderly
patients suffering from chronic diseases. The setting of
the study, the German region of Mecklenburg-Western
Pomerania offers the particular chance to study the effect-
iveness of the proposed intervention in an area particularly
affected by population aging and an increasing number of
people with chronic diseases and multimorbidity [62].
The intervention concept of POLITE-RCT is innovative;
as hospitalization of older, multimorbid, and chronically ill
Figure 2 The flowchart.
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prescribed long-term drugs [39,40], the focus on the
interface between secondary and primary health care is
particularly promising. To our knowledge, this is the
first trial that systematically assesses the effectiveness
of a narrative-based medication review performed bytrained pharmacists. Pharmaceutical recommendation
will be based on both evidence and patient preferences.
Major methodological strengths of the trial include
external monitoring as well as stratified randomization
of participating wards after baseline data collection. This
way, imbalances between intervention and control group
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size requirements will be adapted.
Potential sources of bias include, e.g., the risk of
contamination between intervention and control wards,
interviewer bias, and the risk of low inter-rater reliability.
To reduce the latter, pharmacists will regularly discuss
patient cases and will decide about controversial cases
by consensus.
Conclusion
The POLITE-RCT trial aims at providing robust evi-
dence for the effectiveness of pharmacist-based narrative
medication reviews used at the interface between primary
and secondary health care. In case of positive evaluation,
the proposed study will provide evidence for a sustain-
able reduction of polypharmacy by enhancing patient-
centeredness and patient autonomy. Further, if the trial
provides evidence for the cost-effectiveness of the inter-
vention, policy- and other decision-makers might consider
implementation into routine care.
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